Artiva Biotherapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 10, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 10, 2026
ARTV$4.22+1.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
| YEAR ENDED DECEMBER 31, | ||
|---|---|---|
| 2025 | 2024 | |
| License and development support revenue (including related party amounts of $0 and $251, respectively) | $— | $251 |
| Operating expenses: | ||
| Research and development (including related party amounts of $76 and $3,168, respectively) | 69,540 | 50,328 |
| General and administrative | 20,270 | 17,205 |
| Total operating expenses | 89,810 | 67,533 |
| Loss from operations | (89,810) | (67,282) |
| Other income, net: | ||
| Interest income | 5,959 | 5,349 |
| Change in fair value of SAFEs (including related party amounts of $0 and $2,911, respectively) | — | (3,597) |
| Other (expense) income, net | (14) | 157 |
| Total other income, net | 5,945 | 1,909 |
| Net loss | $(83,865) | $(65,373) |
| Net loss per share, basic and diluted | $(3.43) | $(5.81) |
| Weighted-average common shares outstanding, basic and diluted | 24,444,057 | 11,258,851 |
| Comprehensive loss: | ||
| Net loss | $(83,865) | $(65,373) |
| Other comprehensive income (loss): | ||
| Unrealized gain (loss) on investments, net | 232 | (437) |
| Comprehensive loss | $(83,633) | $(65,810) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.